The FDA alignment on Phase 2 dose and planned pivotal trial for BH-30643 are key catalysts. Monitor enrollment in SOLARA-2 and any updates on accelerated approval pathway. The cash runway into Q2 2028 reduces near-term financing risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $14.02entry
- T+1 · 20h ago −2.64%α −0.73% · $13.65
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BlossomHill Therapeutics reported Q3 2026 net loss of $24.0M ($1.29 per share), wider than the $16.0M loss in Q3 2025, driven by increased R&D spending on lead programs. The company highlighted FDA alignment on a Phase 2 dose for BH-30643 and plans for a pivotal trial, with $224.9M cash expected to fund operations into Q2 2028. Consensus estimates were not available for EPS or revenue, so no surprise or rating is assigned.
Key Financial Metrics
Key Facts
- Net loss of $24.0M ($1.29 per share) for Q3 2026 vs $16.0M ($6.54 per share) in Q3 2025
- Cash and cash equivalents of $224.9M as of September 30, 2026
- FDA alignment on 50 mg BID as recommended Phase 2 dose for BH-30643
- SOLARA-2 pivotal Phase 2 trial for BH-30643 in C797S-positive NSCLC expected to dose first patient in Q1 2027
- IND filing for BH-501284 (pan-KRAS inhibitor) planned for Q1 2027
- R&D expenses increased to $21.9M from $14.7M year-over-year
- Completed IPO in August 2026, raising $168.3M in gross proceeds
Financial Impact
Net loss increased by $8.0M year-over-year; cash position of $224.9M provides runway into Q2 2028
Risk Factors
- Clinical-stage company with no approved products; results depend on trial outcomes
- Net loss widening as R&D spending increases; no revenue expected in near term
- Competition from other EGFR and KRAS inhibitors in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402146 |
Track record
19 reports on BLSM
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +37.56% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $13.65 Now $13.65 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.00 Now $13.65 −2.50% settles Dec 15
- Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $14.02 Now $13.65 −2.64% settles Dec 14
- Sep 28, 20267w ago Press Release Bearish 7/10 Entry $21.34 to $16.39 Now $13.65 +36.04% ▲ +23.20% +23.16% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 No price data
- Sep 18, 20268w ago Press Release Neutral 5/10 Entry $25.74 to $13.94 Now $13.65 −46.97% ▼ −45.84% −46.05% vs SPY
- Sep 15, 20268w ago 8-K Neutral 3/10 Entry $22.17 to $15.48 Now $13.65 −38.43% ▼ −30.18% −33.15% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 8/10 Entry $16.35 to $20.86 Now $13.65 −16.51% ▲ +27.58% +29.33% vs SPY
- Aug 10, 202614w ago Insider Cluster Bullish 7/10 Entry $16.52 to $22.00 Now $13.65 −17.37% ▲ +33.17% +34.23% vs SPY
- Aug 10, 202614w ago 8-K Neutral 4/10 Entry $16.52 to $22.00 Now $13.65 −17.37% ▲ +33.17% +34.23% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers